Alkermes is drafting a former Major League Baseball player who has struggled with his own alcohol addiction as spokesperson for its alcohol dependency awareness campaign. World Series winner and ...

(Reuters) - Drugmaker Alkermes said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for schizophrenia and bipolar disorder, citing concerns related to a tablet ...

The chair of an FDA panel believes the drug Dsuvia represents a “danger” to public health. Just two weeks after a rare rebuke from the Food and Drug Administration derailed Alkermes’s treatment for ...

Alkermes plc (NASDAQ:ALKS) is one of the most promising mid-cap healthcare stocks under $50. At the close of play on December 19, the consensus ratings remain bullish for Alkermes plc (NASDAQ:ALKS).

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

As stripped down and divested Alkermes enters 2024 as a “pure-play neuroscience company”—as described by CEO Richard Pops on a conference call on Thursday—much will depend on the success of new ...

Alkermes plans to spin out its oncology research division into a standalone entity, creating a potential value-unlocking transaction. The spin-off will allow Alkermes to focus on its neuroscience ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

DUBLIN, Sept. 11, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Monday, Sept.

Alkermes has a portfolio of commercialized neuroscience products and a pipeline that spans both neuroscience and cancer. The drugmaker is now exploring the possibility of splitting off its cancer ...